Reimagining Health and Disease

More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes?

Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.

 

By manipulating this system with our unique Gene Traffic ControlTM Product Platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us – and rewrite destiny for millions of people living with disease.

 

With the Gene Traffic ControlTM Product Platform, Foghorn® Therapeutics is discovering and developing an unprecedented class of medicines targeting diseases with genetically determined dependencies in the chromatin regulatory system. The company, currently pre-clinical stage, is rapidly advancing over 10 programs across a wide range of cancers and is beginning to explore other diseases.

 

Foghorn’s proprietary Gene Traffic ControlTM Product Platform is based on the company’s unique insights into the chromatin regulatory system and enables highly scalable drug discovery and development efforts.

a pioneering culture

Foghorn’s focus is on discovering, developing, and delivering revolutionary medicines to our fellow human beings.

We’re building a company that puts people first, never stops trying to battle disease, puts teamwork at the core of everything, and is driven by science to find new ways to think about solving disease.

Meet the minds behind Gene Traffic ControlTM Product Platform

Foghorn envisions a world where we will cure diseases from within. Learn more below about the people working to make this vision a reality.

Sam Agresta

Samuel Agresta, MD, MPH & TM

Chief Medical Officer

Paul Alloway - Head of Legal

Paul Alloway, PhD, JD

VP, Head of Legal

Steven Bellon, PhD - Head of Drug Discovery

Steve Bellon, PhD

SVP, Drug Discovery

Tess Cameron – Finance, Foghorn Therapeutics

Tess Cameron

Senior Director, Finance

Fanny Cavalie - Vice President of Business and Operations

Fanny Cavalié

VP, Business & Operations

Ho Man Chan, PhD, is a member of the leadership team at Foghorn Therapeutics

Ho Man Chan, PhD

VP, Biology and Translational

Carlos Costa - Vice President of People and Organization

Carlos Costa

VP, People & Organization

Carl Decicco, PhD

Carl P. Decicco, PhD

Chief Scientific Officer

Adrian Gottschalk – President & CEO of Foghorn Therapeutics

Adrian Gottschalk

President & CEO

Murphy Hentemann

Murphy Hentemann, PhD

VP, Program Leadership

David Millan, PhD, head of chemistry for Foghorn Therapeutics

David Millan, PhD

VP, Chemistry

Allan Reine

Allan Reine, MD

Chief Financial Officer

Logo for Flagship Pioneering

A unique life science innovation enterprise, Flagship Pioneering conceives, creates, resources and develops first-in-category life sciences companies. Since its launch in 2000, the firm has applied a proprietary, hypothesis-driven innovation process to originate and foster nearly 100 scientific ventures, resulting in over $20 billion in aggregate value, 500+ issued patents and more than 40 clinical trials for novel therapeutic agents.